Pharmacokinetics of milnacipran in liver impairment

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 2, 1998, Pages 273-279

  Puozzo, C ^a   Albin, H ^b   Vincon G ^b   Deprez, D ^a   Raymond, J M ^c   Amouretti, M ^c  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b HÔPITAL PELLEGRIN   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Clinical pharmacokinetics; Glucuronidation; Liver impairment; Milnacipran

Indexed keywords

MILNACIPRAN;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; GLUCURONIDATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION; VOMITING;

EID: 0031716760     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03189351     Document Type: Conference Paper

References (9)

1. Milnacipran hydrochloride, Dalcipran registered trade mark, Toledomin registered trade mark. Drugs Future. 21(1) : 88-89.
2. Pugh RN, Murray-Lyon IM, Dawson JL et al. (1973). Transection of the oesophagus for bleeding oesophagus varices. Br J Surg. 60 : 646-649.
3. Puozzo C, Duchene P, Bromet M, Filaquier C, Zorza G. (1996). Determination of milnacipran (F2207) and its glucuroconjugate in plasma, blood and urines by high performance liquid chromatography with fluorescence detection. J Chromatogr. To be published.
4. Rowland M, Tozer T. (1980). Clinical pharmacokinetics : concepts and applications. Ed Lea Febinger, Philadelphia.
5. Puozzo C, Filaquier C, Briley M. (1985). Plasma levels of F2207, a novel antidepressant, after a single oral administration in volunteers. Br J Clin Pharm. 20 : 291.
6. Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C. (1998). Which bioequivalence for a racemic drug? Application to midlnacipran. Eur J Drug Metab pharmacokinet. 23 (2): 166-171.
7. Mc Lean AJ, Morgan DJ. (1991). Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet. 21(1) : 42-69.
8. Morgan DJ, Mc Lean AJ. (1995). Clinical pharmacokinetics and pharmacodynamic considerations in patients with liver disease - un update, Clin Pharmacokinet. 29(5) : 370-3911.
9. Puozzo C, Pozet N, Deprez D, Baille P, Ung UL, Zech P. (1998). Pharmacokinetics of milnacipran in renal impairment. Eur J Drug Metab pharmacokinet. 23 (2): 280-286.